{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:31:21Z","timestamp":1791721881292,"version":"4.3.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Verona School of Medicine, Verona, Italy","id":[{"id":"https:\/\/ror.org\/039bp8j42","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100031584","name":"Deutsches Zentrum f\u00fcr Diabetesforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031584","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum T\u00fcbingen","id":[{"id":"https:\/\/ror.org\/00pjgxh97","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00125-026-06796-1","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:08:47Z","timestamp":1784286527000},"page":"3148-3161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacological treatment of MASH"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2186-9595","authenticated-orcid":false,"given":"Norbert","family":"Stefan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"3","key":"6796_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VW Wong","year":"2023","unstructured":"Wong VW, Ekstedt M, Wong GL, Hagstr\u00f6m H (2023) Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol 79(3):842\u2013852. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.036","journal-title":"J Hepatol"},{"issue":"11","key":"6796_CR2","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","volume":"72","author":"E En Li Cho","year":"2023","unstructured":"En Li Cho E, Ang CZ, Quek J et al (2023) Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut 72(11):2138\u20132148. https:\/\/doi.org\/10.1136\/gutjnl-2023-330110","journal-title":"Gut"},{"issue":"7","key":"6796_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD (2025) Metabolic dysfunction-associated steatotic liver disease. N Engl J Med 393(7):683\u2013698. https:\/\/doi.org\/10.1056\/NEJMra2412865","journal-title":"N Engl J Med"},{"issue":"2","key":"6796_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","volume":"335","author":"H Tilg","year":"2026","unstructured":"Tilg H, Petta S, Stefan N, Targher G (2026) Metabolic dysfunction-associated steatotic liver disease in adults: a review. JAMA 335(2):163\u2013174. https:\/\/doi.org\/10.1001\/jama.2025.19615","journal-title":"JAMA"},{"issue":"11","key":"6796_CR5","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1007\/s00125-024-06196-3","volume":"67","author":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity","year":"2024","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity (2024) EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive Summary. Diabetologia 67(11):2375\u20132392. https:\/\/doi.org\/10.1007\/s00125-024-06196-3","journal-title":"Diabetologia"},{"issue":"3","key":"6796_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","volume":"162","author":"R Loomba","year":"2022","unstructured":"Loomba R, Ratziu V, Harrison SA, NASH Clinical Trial Design International Working Group (2022) Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis. Gastroenterology 162(3):680\u2013688. https:\/\/doi.org\/10.1053\/j.gastro.2021.10.051","journal-title":"Gastroenterology"},{"key":"6796_CR7","doi-asserted-by":"publisher","unstructured":"Sanyal AJ, Nakajima A, Bugianesi E et al (2025) Expert Delphi consensus on surrogate endpoints for treatment assessment in metabolic dysfunction-associated steatohepatitis. Clin Gastroenterol Hepatol S1542-3565(25)01014-6. https:\/\/doi.org\/10.1016\/j.cgh.2025.12.001","DOI":"10.1016\/j.cgh.2025.12.001"},{"key":"6796_CR8","unstructured":"US Food and Drug Administration (2025) FDA accepts proposal for reasonably likely surrogate endpoint for \u2018MASH\u2019 all-cause mortality or liver-related events. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-accepts-proposal-reasonably-likely-surrogate-endpoint-mash-all-cause-mortality-or-liver-related. Accessed: 20 March 2026"},{"issue":"3","key":"6796_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/gutjnl-2022-327777","volume":"72","author":"R Loomba","year":"2023","unstructured":"Loomba R, Huang DQ, Sanyal AJ et al (2023) Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut 72(3):581\u2013589. https:\/\/doi.org\/10.1136\/gutjnl-2022-327777","journal-title":"Gut"},{"issue":"15","key":"6796_CR10","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2024.1447","volume":"331","author":"H Lin","year":"2024","unstructured":"Lin H, Lee HW, Yip TC et al (2024) Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. JAMA 331(15):1287\u20131297. https:\/\/doi.org\/10.1001\/jama.2024.1447","journal-title":"JAMA"},{"issue":"1","key":"6796_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/HEP.0000000000001658","volume":"84","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Lee HW, Lin H et al (2025) Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease. Hepatology 84(1):175\u2013190. https:\/\/doi.org\/10.1097\/HEP.0000000000001658","journal-title":"Hepatology"},{"issue":"10","key":"6796_CR12","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1136\/gutjnl-2025-335542","volume":"74","author":"G Feng","year":"2025","unstructured":"Feng G, Wong VW, Targher G, Byrne CD, Zheng MH (2025) Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring. Gut 74(10):1741\u20131750. https:\/\/doi.org\/10.1136\/gutjnl-2025-335542","journal-title":"Gut"},{"issue":"10","key":"6796_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S2468-1253(23)00159-0","volume":"8","author":"H Tilg","year":"2023","unstructured":"Tilg H, Byrne CD, Targher G (2023) NASH drug treatment development: challenges and lessons. Lancet Gastroenterol Hepatol 8(10):943\u2013954. https:\/\/doi.org\/10.1016\/S2468-1253(23)00159-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"6796_CR14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.31518","volume":"73","author":"H Tilg","year":"2021","unstructured":"Tilg H, Adolph TE, Moschen AR (2021) Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade. Hepatology 73(2):833\u2013842. https:\/\/doi.org\/10.1002\/hep.31518","journal-title":"Hepatology"},{"issue":"18","key":"6796_CR15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1042\/CS20257571","volume":"139","author":"WH Lee","year":"2025","unstructured":"Lee WH, Kipp ZA, Bates EA, Pauss SN, Martinez GJ, Hinds TD Jr (2025) The physiology of MASLD: molecular pathways between liver and adipose tissues. Clin Sci (Lond) 139(18):1015\u20131046. https:\/\/doi.org\/10.1042\/CS20257571","journal-title":"Clin Sci (Lond)"},{"issue":"5","key":"6796_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41575-025-01045-z","volume":"22","author":"CD Byrne","year":"2025","unstructured":"Byrne CD, Armandi A, Pellegrinelli V, Vidal-Puig A, Bugianesi E (2025) \u039cetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment. Nat Rev Gastroenterol Hepatol 22(5):314\u2013328. https:\/\/doi.org\/10.1038\/s41575-025-01045-z","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"6796_CR17","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al (2023) AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5):1797\u20131835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"key":"6796_CR18","doi-asserted-by":"publisher","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149(2):367\u201378.e5; quiz e14-5. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005","DOI":"10.1053\/j.gastro.2015.04.005"},{"issue":"3","key":"6796_CR19","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","volume":"160","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Corey KE, Lim JK (2021) AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology 160(3):912\u2013918. https:\/\/doi.org\/10.1053\/j.gastro.2020.11.051","journal-title":"Gastroenterology"},{"issue":"6","key":"6796_CR20","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","volume":"76","author":"V Ratziu","year":"2022","unstructured":"Ratziu V, Francque S, Sanyal A (2022) Breakthroughs in therapies for NASH and remaining challenges. J Hepatol 76(6):1263\u20131278. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.002","journal-title":"J Hepatol"},{"issue":"5","key":"6796_CR21","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","volume":"36","author":"MA Tincopa","year":"2024","unstructured":"Tincopa MA, Anstee QM, Loomba R (2024) New and emerging treatments for metabolic dysfunction-associated steatohepatitis. Cell Metab 36(5):912\u2013926. https:\/\/doi.org\/10.1016\/j.cmet.2024.03.011","journal-title":"Cell Metab"},{"issue":"2","key":"6796_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan N, Yki-J\u00e4rvinen H, Neuschwander-Tetri BA (2025) Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol 13(2):134\u2013148. https:\/\/doi.org\/10.1016\/S2213-8587(24)00318-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"6796_CR23","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2025) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S183\u2013S215. https:\/\/doi.org\/10.2337\/dc26-S009","journal-title":"Diabetes Care"},{"issue":"7","key":"6796_CR24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM et al (2025) Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care 48(7):1057\u20131082. https:\/\/doi.org\/10.2337\/dci24-0094","journal-title":"Diabetes Care"},{"issue":"7","key":"6796_CR25","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP et al (2024) Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med 30(7):2037\u20132048. https:\/\/doi.org\/10.1038\/s41591-024-03018-2","journal-title":"Nat Med"},{"issue":"3","key":"6796_CR26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","volume":"163","author":"MT Long","year":"2022","unstructured":"Long MT, Noureddin M, Lim JK (2022) AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology 163(3):764-774.e1. https:\/\/doi.org\/10.1053\/j.gastro.2022.06.023","journal-title":"Gastroenterology"},{"issue":"2","key":"6796_CR27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cmet.2017.07.008","volume":"26","author":"N Stefan","year":"2017","unstructured":"Stefan N, Schick F, H\u00e4ring HU (2017) Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab 26(2):292\u2013300. https:\/\/doi.org\/10.1016\/j.cmet.2017.07.008","journal-title":"Cell Metab"},{"issue":"7","key":"6796_CR28","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S2213-8587(20)30110-8","volume":"8","author":"N Stefan","year":"2020","unstructured":"Stefan N (2020) Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol 8(7):616\u2013627. https:\/\/doi.org\/10.1016\/S2213-8587(20)30110-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"6796_CR29","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I et al (2024) Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 12(7):447\u2013461. https:\/\/doi.org\/10.1016\/S2213-8587(24)00102-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6796_CR30","doi-asserted-by":"publisher","unstructured":"McLean P, Bennett J, \u201cTrey\u201d Woods E et al (2025) SGLT2 inhibitors across various patient populations in the era of precision medicine: the multidisciplinary team approach. npj Metab Health Dis 3, 29 (2025). https:\/\/doi.org\/10.1038\/s44324-025-00068-z","DOI":"10.1038\/s44324-025-00068-z"},{"issue":"9","key":"6796_CR31","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K et al (2022) Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care 45(9):2064\u20132075. https:\/\/doi.org\/10.2337\/dc21-2049","journal-title":"Diabetes Care"},{"key":"6796_CR32","doi-asserted-by":"publisher","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, Huang Y, Xu B et al (2025) Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ 389:e083735. https:\/\/doi.org\/10.1136\/bmj-2024-083735","journal-title":"BMJ"},{"issue":"6","key":"6796_CR33","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.2337\/dc25-0282","volume":"48","author":"A Mantovani","year":"2025","unstructured":"Mantovani A, Morandin R, Lando MG et al (2025) Sodium-glucose cotransporter 2 inhibitor use and risk of liver-related events in patients with type 2 diabetes: a meta-analysis of observational cohort studies. Diabetes Care 48(6):1042\u20131052. https:\/\/doi.org\/10.2337\/dc25-0282","journal-title":"Diabetes Care"},{"issue":"6706","key":"6796_CR34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1126\/science.adn4128","volume":"385","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ (2024) The benefits of GLP-1 drugs beyond obesity. Science 385(6706):258\u2013260. https:\/\/doi.org\/10.1126\/science.adn4128","journal-title":"Science"},{"issue":"12","key":"6796_CR35","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384(12):1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"issue":"21","key":"6796_CR36","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I et al (2025) Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 392(21):2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"issue":"6","key":"6796_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ et al (2023) Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 8(6):511\u2013522. https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6796_CR38","unstructured":"US Food and Drug Administration (2025) FDA approves treatment for serious liver disease known as \u2018MASH\u2019. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash. Accessed: 20 March 2026"},{"key":"6796_CR39","unstructured":"European Medicines Agency (2026) Kayshild. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kayshild. Accessed: 4 May 2026"},{"issue":"9","key":"6796_CR40","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.cmet.2023.07.010","volume":"35","author":"JE Campbell","year":"2023","unstructured":"Campbell JE, M\u00fcller TD, Finan B, DiMarchi RD, Tsch\u00f6p MH, D\u2019Alessio DA (2023) GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metab 35(9):1519\u20131529. https:\/\/doi.org\/10.1016\/j.cmet.2023.07.010","journal-title":"Cell Metab"},{"issue":"7","key":"6796_CR41","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1007\/s00125-024-06144-1","volume":"67","author":"T Karagiannis","year":"2024","unstructured":"Karagiannis T, Malandris K, Avgerinos I et al (2024) Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia 67(7):1206\u20131222. https:\/\/doi.org\/10.1007\/s00125-024-06144-1","journal-title":"Diabetologia"},{"issue":"1","key":"6796_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW et al (2025) Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 393(1):26\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2416394","journal-title":"N Engl J Med"},{"issue":"4","key":"6796_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ et al (2024) Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"issue":"11","key":"6796_CR44","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.2337\/db14-0242","volume":"63","author":"J Cegla","year":"2014","unstructured":"Cegla J, Troke RC, Jones B et al (2014) Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63(11):3711\u20133720. https:\/\/doi.org\/10.2337\/db14-0242","journal-title":"Diabetes"},{"issue":"4","key":"6796_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M et al (2024) A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 391(4):311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa2401755","journal-title":"N Engl J Med"},{"issue":"2","key":"6796_CR46","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","volume":"29","author":"SA Kliewer","year":"2019","unstructured":"Kliewer SA, Mangelsdorf DJ (2019) A dozen years of discovery: insights into the physiology and pharmacology of FGF21. Cell Metab 29(2):246\u2013253. https:\/\/doi.org\/10.1016\/j.cmet.2019.01.004","journal-title":"Cell Metab"},{"issue":"2","key":"6796_CR47","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cmet.2023.01.006","volume":"35","author":"N Stefan","year":"2023","unstructured":"Stefan N, Schick F, Birkenfeld AL, H\u00e4ring HU, White MF (2023) The role of hepatokines in NAFLD. Cell Metab 35(2):236\u2013252. https:\/\/doi.org\/10.1016\/j.cmet.2023.01.006","journal-title":"Cell Metab"},{"issue":"11","key":"6796_CR48","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, Sanyal AJ, Kowdley KV et al (2023) Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med 389(11):998\u20131008. https:\/\/doi.org\/10.1056\/NEJMoa2304286","journal-title":"N Engl J Med"},{"issue":"10504","key":"6796_CR49","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","volume":"406","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Frias JP, Neff GW et al (2025) Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 406(10504):719\u2013730. https:\/\/doi.org\/10.1016\/S0140-6736(25)01073-6","journal-title":"Lancet"},{"issue":"9","key":"6796_CR50","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1089\/thy.2018.0664","volume":"29","author":"RA Sinha","year":"2019","unstructured":"Sinha RA, Bruinstroop E, Singh BK, Yen PM (2019) Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists. Thyroid 29(9):1173\u20131191. https:\/\/doi.org\/10.1089\/thy.2018.0664","journal-title":"Thyroid"},{"issue":"6","key":"6796_CR51","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD et al (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"6796_CR52","unstructured":"US Food and Drug Administration (2024) FDA approves first treatment for patients with liver scarring due to fatty liver disease. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease. Accessed: 20 March 2026."},{"key":"6796_CR53","unstructured":"European Medicines Agency (2025) First treatment against liver scarring caused by a type of \u2018fatty liver disease\u2019. Available from: https:\/\/www.ema.europa.eu\/en\/news\/first-treatment-against-liver-scarring-caused-type-fatty-liver-disease. Accessed: 20 March 2026"},{"issue":"1","key":"6796_CR54","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","volume":"18","author":"S Francque","year":"2021","unstructured":"Francque S, Szabo G, Abdelmalek MF et al (2021) Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol 18(1):24\u201339. https:\/\/doi.org\/10.1038\/s41575-020-00366-5","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"6796_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/1479164118825376","volume":"16","author":"RA DeFronzo","year":"2019","unstructured":"DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE (2019) Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res 16(2):133\u2013143. https:\/\/doi.org\/10.1177\/1479164118825376","journal-title":"Diab Vasc Dis Res"},{"issue":"5","key":"6796_CR56","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","volume":"177","author":"G Musso","year":"2017","unstructured":"Musso G, Cassader M, Paschetta E, Gambino R (2017) Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 177(5):633\u2013640. https:\/\/doi.org\/10.1001\/jamainternmed.2016.9607","journal-title":"JAMA Intern Med"},{"issue":"2","key":"6796_CR57","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1210\/clinem\/dgac624","volume":"108","author":"R Belfort-DeAguiar","year":"2023","unstructured":"Belfort-DeAguiar R, Lomonaco R, Cusi K (2023) Approach to the patient with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 108(2):483\u2013495. https:\/\/doi.org\/10.1210\/clinem\/dgac624","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"6796_CR58","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V et al (2021) A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH. N Engl J Med 385(17):1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMoa2036205","journal-title":"N Engl J Med"},{"issue":"8","key":"6796_CR59","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41575-025-01096-2","volume":"22","author":"H Tilg","year":"2025","unstructured":"Tilg H, Targher G (2025) Lessons from incretin-based therapy in MASH and obesity. Nat Rev Gastroenterol Hepatol 22(8):531\u2013533. https:\/\/doi.org\/10.1038\/s41575-025-01096-2","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"6796_CR60","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","volume":"49","author":"A Ismaiel","year":"2025","unstructured":"Ismaiel A, Scarlata GGM, Boitos I et al (2025) Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. Int J Obes (Lond) 49(10):1946\u20131957. https:\/\/doi.org\/10.1038\/s41366-025-01859-6","journal-title":"Int J Obes (Lond)"},{"issue":"8","key":"6796_CR61","doi-asserted-by":"publisher","first-page":"e2526327","DOI":"10.1001\/jamanetworkopen.2025.26327","volume":"8","author":"L Wang","year":"2025","unstructured":"Wang L, Volkow ND, Kaelber DC, Xu R (2025) Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Netw Open 8(8):e2526327. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.26327","journal-title":"JAMA Netw Open"},{"issue":"1","key":"6796_CR62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S2213-8587(22)00340-0","volume":"11","author":"AY Dawed","year":"2023","unstructured":"Dawed AY, Mari A, Brown A et al (2023) Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol 11(1):33\u201341. https:\/\/doi.org\/10.1016\/S2213-8587(22)00340-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"6796_CR63","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","volume":"30","author":"V Raverdy","year":"2024","unstructured":"Raverdy V, Tavaglione F, Chatelain E et al (2024) Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med 30(12):3624\u20133633. https:\/\/doi.org\/10.1038\/s41591-024-03283-1","journal-title":"Nat Med"},{"issue":"12","key":"6796_CR64","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","volume":"30","author":"O Jamialahmadi","year":"2024","unstructured":"Jamialahmadi O, De Vincentis A, Tavaglione F et al (2024) Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med 30(12):3614\u20133623. https:\/\/doi.org\/10.1038\/s41591-024-03284-0","journal-title":"Nat Med"},{"issue":"4","key":"6796_CR65","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41575-025-01048-w","volume":"22","author":"N Stefan","year":"2025","unstructured":"Stefan N, Targher G (2025) Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine. Nat Rev Gastroenterol Hepatol 22(4):226\u2013227. https:\/\/doi.org\/10.1038\/s41575-025-01048-w","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"6796_CR66","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S2213-8587(23)00086-4","volume":"11","author":"N Stefan","year":"2023","unstructured":"Stefan N, Schulze MB (2023) Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment. Lancet Diabetes Endocrinol 11(6):426\u2013440. https:\/\/doi.org\/10.1016\/S2213-8587(23)00086-4","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"13","key":"6796_CR67","doi-asserted-by":"publisher","first-page":"e186425","DOI":"10.1172\/JCI186425","volume":"135","author":"PN Newsome","year":"2025","unstructured":"Newsome PN, Loomba R (2025) Therapeutic horizons in metabolic dysfunction-associated steatohepatitis. J Clin Invest 135(13):e186425. https:\/\/doi.org\/10.1172\/JCI186425","journal-title":"J Clin Invest"},{"issue":"4","key":"6796_CR68","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/gutjnl-2025-337431","volume":"75","author":"XD Zhou","year":"2026","unstructured":"Zhou XD, Fan QY, Byrne CD et al (2026) Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities. Gut 75(4):815\u2013825. https:\/\/doi.org\/10.1136\/gutjnl-2025-337431","journal-title":"Gut"},{"issue":"4","key":"6796_CR69","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1111\/dom.70507","volume":"28","author":"SA Polyzos","year":"2026","unstructured":"Polyzos SA, Kountouras J, Duntas LH, Targher G (2026) Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction-associated steatohepatitis? Diabetes Obes Metab 28(4):2507\u20132510. https:\/\/doi.org\/10.1111\/dom.70507","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06796-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06796-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06796-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:39:17Z","timestamp":1790771957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06796-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["6796"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06796-1","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. This work was aided in part by funding from the German Center for Diabetes Research (DZD) to NS. GT is supported in part by the University of Verona School of Medicine, Verona, Italy.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"NS has been or is a consultant and has given scientific talks for Allergan, AstraZeneca, Boehringer Ingelheim, Gilead, Genkyotex, GSK, Intercept Pharma, Lilly, MSD, Novartis, Novo Nordisk, Pfizer and Sanofi. NS has also received research support from AstraZeneca, Boehringer Ingelheim, Sanofi, DSM Nutritional Products and Roche Diagnostics. GT declares that there are no relationships or activities that might bias, or be perceived to bias, his work.","order":2,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Both authors were responsible for drafting and critically reviewing the article. Both authors approved the version to be published.","order":3,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}